FDA Inspection 1014251 — MetaGen Corp.

MetaGen Corp. — FEI 3008787557

The FDA completed an inspection of MetaGen Corp. on June 14, 2017 in Belmont, MA. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). 3 citations were issued during this inspection. Product area: Biologics.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
June 14, 2017
Fiscal Year
2017
Product Type
Biologics
Project Area
Human Cellular, Tissue, and Gene Therapies
Location
Belmont, MA (United States)

Citations

IDCFRDescription
1233621 CFR 1271.180(a)Procedures to meet core CTGP
1243521 CFR 1271.270(a)Records maintained concurrently
1244721 CFR 1271.290(b)Establishing a system